AlphaYou
Overview
Key stats
Fundamentals Sep 10- Open
- $257.07
- 52-wk high
- $495.55
- High
- $261.98
- 52-wk low
- $197.81
- Low
- $253.28
- Prev close
- $260.10
- Mkt cap
- $34.52B
- P/E
- 45.3x
- Volume
- 1.43M
- Fwd P/E
- 20.4x
- Beta
- 0.30
- P/S
- 7.2x
- P/B
- 25.7x
- Profit margin
- +16.1%
- Op margin
- +17.9%
- ROE
- +96.6%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsSmart money
8 funds hold a position and insiders have been net selling.
What funds are doing
Earnings
Earnings came in 16.0% below what analysts expected.
Earnings per share
$1.44 expected
Revenue
No comparable estimate
Company adjusted EPS
From the company's release
The company and the analyst consensus count earnings differently, so the two figures differ. The comparison above uses the analyst basis.
FY 2026 guidance
$4.70B to $5.10B
No comparable estimate
Reports Oct 29, 2026, in 49 days
EPS expected
$1.94 to $3.45
Revenue expected
21 analysts
Last 30 days
Analysts cutting estimates
What the company said
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $1.25B | $1.10B | $1.17B | $1.29B |
| Cost of what it sold | $197.2M | $267.7M | $211.1M | $298.3M |
| Gross profit | $1.05B | $829.3M | $956.1M | $992.7M |
| What it spent | ||||
| Research and development | $358.8M | $372.2M | $364.9M | $413.1M |
| Sales and admin | $322.1M | $325.4M | $322.6M | $347.9M |
| Total operating expenses | $683.8M | $697.6M | $687.4M | $761.2M |
| What was left | ||||
| Operating profit | $368.0M | $131.7M | $268.6M | $231.4M |
| Interest on debt | $44.4M | $129.3M | $69.3M | $82.1M |
| Profit before tax | $239.0M | $161.1M | $221.7M | $177.8M |
| Tax | -$12.1M | -$25.3M | -$15.7M | $13.3M |
| Net profit | $251.1M | $186.4M | $206.0M | $164.5M |
| EBITDA | $297.2M | $304.0M | $304.5M | $244.7M |
Technicals
Price structure
This stock is trending upward.
Trend
Constructive
75 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
News
What the news says
Coverage is bullish
Tone of tracked coverage
Alnylam to Webcast Presentations at Upcoming September Investor Conferences
NeutralSep 2Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR
BullishAug 31Alnylam stock maintained at Buy by Truist on mixed trial data
NeutralAug 31Alnylam's Latest Data Strengthen Outlook for Nucresiran, TRITON-CM, Oppenheimer Says
BullishAug 31If You Invested $100 In Alnylam Pharmaceuticals Stock 20 Years Ago, You Would Have This Much Today
Leans bullishAug 30
Macro
20 macro signals shaping ALNY right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results